Adaptive Biotechnologies
Leveraging the adaptive immune system to diagnose and treat disease.
About
Technology stack
detected 2026-06-17No comments yet. Be the first to share your take.
What does Adaptive Biotechnologies do?
Adaptive Biotechnologies harnesses the adaptive immune system to power the Age of Immune Medicine, translating immune system genetics into actionable data. Their core offerings include clonoSEQ for Measurable Residual Disease assessment and an Immune Medicine Platform that informs clinical trials and the development of transformative medicines. They serve clinicians, biopharma companies, and patients by transforming how diseases are detected, monitored, and treated.
How much funding has Adaptive Biotechnologies raised?
Adaptive Biotechnologies has raised a total of $300M in funding. The most recent round on record is Series D.
Where is Adaptive Biotechnologies headquartered?
Adaptive Biotechnologies is headquartered in Seattle, United States.
When was Adaptive Biotechnologies founded?
Adaptive Biotechnologies was founded in 2009.
What industry does Adaptive Biotechnologies operate in?
Adaptive Biotechnologies operates in Biotech, HealthTech, Genomics, Drug Discovery, Clinical Trials, Diagnostics.